SurVaxM

SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.

While vaccines are typically thought of as ways to prevent diseases, vaccines can also be used in a therapeutic mode (e.g., to treat cancer). SurVaxM is delivered through simple subcutaneous injection.

Malignant Glioma (GBM):

SurVaxM demonstrated safety and tolerability in a Phase I study in patients with recurrent or progressive malignant glioma (brain tumors). View press release

SurVaxM has now entered a Phase II clinical trial in adults with newly diagnosed glioblastoma. at leading cancer centers: Roswell Park Cancer Institute, Cleveland Clinic and Dana-Farber Cancer Institute. Please visit the Clinical Trials page for more information.

Although SurVaxM was first tested in brain cancer, survivin is present in most cancers, including multiple myeloma, melanoma, ovarian, renal, lymphoma, prostate and breast cancers. Thus SurVaxM could have broad applicability to these cancers.

Multiple Myeloma:

A Phase I clinical trial evaluating SurVaxM in combination with REVLIMID®(lenalidomide) as a maintenance therapy for adults with multiple myeloma has been initiated with support from Celgene (marketer of REVLIMID®). Please visit the Clinical Trials page for more information.

MimiVax has an exclusive license to globally commercialize SurVaxM, as well as an extensive worldwide patent portfolio for SurVaxM and other products in development.